Concepts (170)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Clinical Clerkship | 4 | 2015 | 117 | 0.600 |
Why?
|
| Radiation Oncology | 4 | 2015 | 130 | 0.590 |
Why?
|
| Program Evaluation | 4 | 2018 | 349 | 0.470 |
Why?
|
| Clinical Competence | 4 | 2018 | 873 | 0.420 |
Why?
|
| Vitreoscilla | 2 | 2013 | 2 | 0.400 |
Why?
|
| Dietetics | 1 | 2013 | 3 | 0.390 |
Why?
|
| Nutritionists | 1 | 2013 | 3 | 0.390 |
Why?
|
| Truncated Hemoglobins | 1 | 2013 | 1 | 0.390 |
Why?
|
| Professional Role | 1 | 2013 | 40 | 0.370 |
Why?
|
| Tyrosine | 1 | 2013 | 135 | 0.370 |
Why?
|
| Carbon Monoxide | 1 | 2013 | 100 | 0.370 |
Why?
|
| Needs Assessment | 2 | 2014 | 174 | 0.350 |
Why?
|
| Research | 1 | 2013 | 258 | 0.340 |
Why?
|
| Oxygen | 1 | 2013 | 777 | 0.260 |
Why?
|
| Bacterial Proteins | 1 | 2013 | 901 | 0.250 |
Why?
|
| Students, Medical | 4 | 2015 | 450 | 0.220 |
Why?
|
| Brachytherapy | 2 | 2021 | 139 | 0.220 |
Why?
|
| Plant Proteins | 3 | 2008 | 131 | 0.190 |
Why?
|
| Allergens | 3 | 2008 | 196 | 0.190 |
Why?
|
| Methylmethacrylate | 1 | 2002 | 6 | 0.180 |
Why?
|
| Career Choice | 2 | 2014 | 167 | 0.180 |
Why?
|
| Spinal Cord Compression | 1 | 2002 | 50 | 0.170 |
Why?
|
| Thoracic Vertebrae | 1 | 2002 | 89 | 0.170 |
Why?
|
| Radiotherapy, Image-Guided | 1 | 2021 | 66 | 0.160 |
Why?
|
| Prostheses and Implants | 1 | 2002 | 132 | 0.160 |
Why?
|
| Curriculum | 3 | 2015 | 643 | 0.160 |
Why?
|
| Spinal Neoplasms | 1 | 2002 | 128 | 0.160 |
Why?
|
| Crystallography, X-Ray | 6 | 2013 | 532 | 0.160 |
Why?
|
| Decompression, Surgical | 1 | 2002 | 171 | 0.150 |
Why?
|
| Escherichia coli | 4 | 2013 | 572 | 0.140 |
Why?
|
| Palliative Medicine | 1 | 2018 | 11 | 0.140 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2021 | 326 | 0.140 |
Why?
|
| Lumbar Vertebrae | 1 | 2002 | 376 | 0.130 |
Why?
|
| Tumor Necrosis Factor Ligand Superfamily Member 15 | 2 | 2007 | 7 | 0.130 |
Why?
|
| Crystallization | 8 | 2008 | 219 | 0.120 |
Why?
|
| Protein Structure, Tertiary | 4 | 2013 | 733 | 0.120 |
Why?
|
| Spinal Fusion | 1 | 2002 | 373 | 0.120 |
Why?
|
| Recombinant Proteins | 4 | 2013 | 994 | 0.120 |
Why?
|
| Protein Structure, Secondary | 3 | 2013 | 342 | 0.120 |
Why?
|
| Glucagon-Like Peptide 1 | 1 | 2015 | 65 | 0.110 |
Why?
|
| Data Collection | 2 | 2014 | 376 | 0.110 |
Why?
|
| Medical Oncology | 1 | 2018 | 426 | 0.100 |
Why?
|
| Education, Medical, Graduate | 1 | 2018 | 455 | 0.100 |
Why?
|
| Queensland | 1 | 2013 | 5 | 0.100 |
Why?
|
| Carcinoma, Large Cell | 1 | 2013 | 38 | 0.100 |
Why?
|
| Pediatrics | 1 | 2018 | 422 | 0.100 |
Why?
|
| Achievement | 1 | 2013 | 30 | 0.100 |
Why?
|
| Phenylalanine | 1 | 2013 | 31 | 0.100 |
Why?
|
| Proline | 1 | 2013 | 51 | 0.090 |
Why?
|
| Alanine | 1 | 2013 | 82 | 0.090 |
Why?
|
| Models, Molecular | 3 | 2013 | 1397 | 0.090 |
Why?
|
| Employment | 1 | 2013 | 67 | 0.090 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2013 | 273 | 0.090 |
Why?
|
| Cell Cycle Proteins | 2 | 2005 | 420 | 0.090 |
Why?
|
| Globulins | 2 | 2008 | 2 | 0.090 |
Why?
|
| Perception | 1 | 2013 | 190 | 0.090 |
Why?
|
| Ligands | 1 | 2013 | 492 | 0.090 |
Why?
|
| Insulin-Secreting Cells | 1 | 2015 | 453 | 0.080 |
Why?
|
| Seeds | 2 | 2008 | 62 | 0.080 |
Why?
|
| Antigens, Plant | 2 | 2007 | 14 | 0.080 |
Why?
|
| Chemoradiotherapy | 1 | 2013 | 337 | 0.080 |
Why?
|
| Multivariate Analysis | 1 | 2013 | 1007 | 0.080 |
Why?
|
| Mortality | 1 | 2011 | 160 | 0.080 |
Why?
|
| MicroRNAs | 1 | 2015 | 609 | 0.080 |
Why?
|
| Binding Sites | 1 | 2013 | 1162 | 0.080 |
Why?
|
| Neoadjuvant Therapy | 1 | 2013 | 477 | 0.070 |
Why?
|
| Corylus | 1 | 2008 | 1 | 0.070 |
Why?
|
| Glioblastoma | 1 | 2011 | 301 | 0.070 |
Why?
|
| Ginkgo biloba | 1 | 2008 | 7 | 0.070 |
Why?
|
| Internship and Residency | 1 | 2018 | 1132 | 0.070 |
Why?
|
| Humans | 16 | 2021 | 98799 | 0.070 |
Why?
|
| Pinus | 1 | 2007 | 5 | 0.070 |
Why?
|
| Bertholletia | 1 | 2007 | 1 | 0.070 |
Why?
|
| Survival Rate | 3 | 2013 | 2057 | 0.070 |
Why?
|
| Cryotherapy | 1 | 2007 | 31 | 0.070 |
Why?
|
| Arachis | 1 | 2007 | 13 | 0.070 |
Why?
|
| X-Ray Diffraction | 4 | 2008 | 131 | 0.060 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2013 | 1107 | 0.060 |
Why?
|
| Salvage Therapy | 1 | 2007 | 241 | 0.060 |
Why?
|
| Adenocarcinoma | 1 | 2013 | 1215 | 0.060 |
Why?
|
| Brain Neoplasms | 1 | 2011 | 845 | 0.060 |
Why?
|
| Thioredoxins | 1 | 2005 | 12 | 0.050 |
Why?
|
| Follow-Up Studies | 3 | 2013 | 4049 | 0.050 |
Why?
|
| Spliceosomes | 1 | 2005 | 51 | 0.050 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2013 | 1177 | 0.050 |
Why?
|
| Prostatectomy | 1 | 2007 | 491 | 0.050 |
Why?
|
| Adult | 6 | 2021 | 29698 | 0.050 |
Why?
|
| Female | 6 | 2021 | 51997 | 0.050 |
Why?
|
| Neoplasm Staging | 2 | 2021 | 2087 | 0.050 |
Why?
|
| Neoplasms | 1 | 2018 | 3382 | 0.040 |
Why?
|
| Protein Engineering | 1 | 2003 | 159 | 0.040 |
Why?
|
| Male | 6 | 2014 | 47475 | 0.040 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2003 | 557 | 0.040 |
Why?
|
| Cause of Death | 1 | 2002 | 279 | 0.040 |
Why?
|
| Radiotherapy Dosage | 1 | 2021 | 478 | 0.040 |
Why?
|
| Lung Neoplasms | 1 | 2013 | 2474 | 0.040 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2007 | 1538 | 0.040 |
Why?
|
| Uterus | 1 | 2021 | 233 | 0.040 |
Why?
|
| Retrospective Studies | 3 | 2021 | 11104 | 0.040 |
Why?
|
| Combined Modality Therapy | 2 | 2013 | 1754 | 0.030 |
Why?
|
| Training Support | 1 | 2018 | 23 | 0.030 |
Why?
|
| Interdisciplinary Studies | 1 | 2018 | 19 | 0.030 |
Why?
|
| Aged | 4 | 2018 | 21986 | 0.030 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 2 | 2008 | 238 | 0.030 |
Why?
|
| Molecular Sequence Data | 3 | 2007 | 2897 | 0.030 |
Why?
|
| Seed Storage Proteins | 2 | 2007 | 2 | 0.030 |
Why?
|
| Middle Aged | 4 | 2021 | 29642 | 0.030 |
Why?
|
| Protein Structure, Quaternary | 2 | 2007 | 105 | 0.030 |
Why?
|
| Transcription Factors | 1 | 2005 | 1724 | 0.030 |
Why?
|
| Aged, 80 and over | 2 | 2013 | 7461 | 0.030 |
Why?
|
| Prostatic Neoplasms | 1 | 2007 | 1846 | 0.030 |
Why?
|
| Plant Extracts | 2 | 2008 | 252 | 0.030 |
Why?
|
| Isoquinolines | 1 | 2015 | 58 | 0.030 |
Why?
|
| Cohort Studies | 2 | 2013 | 3242 | 0.030 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 1 | 2015 | 119 | 0.030 |
Why?
|
| Cyclic AMP | 1 | 2015 | 277 | 0.030 |
Why?
|
| Cloning, Molecular | 2 | 2005 | 582 | 0.030 |
Why?
|
| Boston | 1 | 2014 | 42 | 0.030 |
Why?
|
| Consumer Behavior | 1 | 2014 | 35 | 0.020 |
Why?
|
| Hospitals, Teaching | 1 | 2014 | 117 | 0.020 |
Why?
|
| Self Concept | 1 | 2014 | 141 | 0.020 |
Why?
|
| Program Development | 1 | 2014 | 141 | 0.020 |
Why?
|
| Sulfonamides | 1 | 2015 | 352 | 0.020 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2015 | 1256 | 0.020 |
Why?
|
| Base Sequence | 2 | 2007 | 2224 | 0.020 |
Why?
|
| Glucose | 1 | 2015 | 706 | 0.020 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2014 | 215 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2002 | 2680 | 0.020 |
Why?
|
| United States | 2 | 2018 | 8387 | 0.020 |
Why?
|
| Internet | 1 | 2014 | 359 | 0.020 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2011 | 172 | 0.020 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2015 | 642 | 0.020 |
Why?
|
| SEER Program | 1 | 2011 | 252 | 0.020 |
Why?
|
| Postoperative Complications | 1 | 2002 | 2719 | 0.020 |
Why?
|
| Insulin | 1 | 2015 | 1226 | 0.020 |
Why?
|
| Young Adult | 2 | 2014 | 7598 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2018 | 3058 | 0.020 |
Why?
|
| Soybean Proteins | 1 | 2008 | 5 | 0.020 |
Why?
|
| Rats | 1 | 2015 | 4079 | 0.020 |
Why?
|
| Salts | 1 | 2008 | 18 | 0.020 |
Why?
|
| Chicago | 1 | 2014 | 1520 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2015 | 2913 | 0.020 |
Why?
|
| Diffusion | 1 | 2008 | 95 | 0.020 |
Why?
|
| Chromatography, Gel | 1 | 2007 | 96 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2015 | 3628 | 0.020 |
Why?
|
| Urination | 1 | 2007 | 39 | 0.020 |
Why?
|
| Food Hypersensitivity | 1 | 2008 | 90 | 0.020 |
Why?
|
| Hypersensitivity | 1 | 2008 | 167 | 0.020 |
Why?
|
| Solubility | 1 | 2007 | 187 | 0.020 |
Why?
|
| Sequence Alignment | 1 | 2007 | 353 | 0.020 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2007 | 161 | 0.020 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2015 | 1293 | 0.020 |
Why?
|
| Androgen Antagonists | 1 | 2007 | 157 | 0.010 |
Why?
|
| Child | 1 | 2018 | 7771 | 0.010 |
Why?
|
| Restriction Mapping | 1 | 2005 | 119 | 0.010 |
Why?
|
| Prognosis | 1 | 2013 | 4139 | 0.010 |
Why?
|
| Disease-Free Survival | 1 | 2007 | 1196 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 2007 | 2011 | 0.010 |
Why?
|
| HIV Integrase | 1 | 2003 | 5 | 0.010 |
Why?
|
| Cytochromes b | 1 | 2003 | 13 | 0.010 |
Why?
|
| Protein Subunits | 1 | 2003 | 121 | 0.010 |
Why?
|
| Color | 1 | 2003 | 80 | 0.010 |
Why?
|
| Hemoglobins | 1 | 2003 | 197 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 2005 | 895 | 0.010 |
Why?
|
| Time Factors | 1 | 2011 | 5586 | 0.010 |
Why?
|
| Genetic Vectors | 1 | 2003 | 425 | 0.010 |
Why?
|
| Mice | 1 | 2015 | 12762 | 0.010 |
Why?
|
| Nuclear Proteins | 1 | 2005 | 757 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2011 | 9806 | 0.010 |
Why?
|
| Animals | 1 | 2015 | 29045 | 0.010 |
Why?
|